Table 3

Adjusted ORs for microvascular disease prevalence at the end of follow-up overall and stratified by treatment assignmenta

Baseline log2-scale PFAS concentrationOverall N = 877 (252 cases)Placebo n = 436 (141 cases)Lifestyle n = 441 (111 cases)Treatment∗PFAS interaction P
OR (95% CI)OR (95% CI)OR (95% CI)Pinteraction
Sum PFAS1.19 (0.98, 1.45)1.10 (0.83, 1.44)1.40 (1.00, 1.93)0.24
PFOS1.17 (0.98, 1.39)1.07 (0.84, 1.36)1.37 (1.04, 1.84)0.25
 n-PFOS1.16 (0.98, 1.37)1.05 (0.84, 1.33)1.40 (1.06, 1.86)0.17
 Sm-PFOS1.14 (0.97, 1.35)1.11 (0.88, 1.40)1.24 (0.96, 1.61)0.62
 Sm2-PFOS1.18 (1.04, 1.35)1.16 (0.97, 1.39)1.25 (1.02, 1.54)0.62
PFOA1.04 (0.85, 1.27)1.07 (0.80, 1.43)1.05 (0.78, 1.42)0.84
 n-PFOA1.04 (0.84, 1.28)1.04 (0.76, 1.41)1.09 (0.79, 1.49)0.68
 Sb-PFOA1.06 (0.95, 1.19)1.13 (0.96, 1.32)0.99 (0.84, 1.18)0.53
PFHxS1.07 (0.92, 1.23)0.99 (0.79, 1.23)1.17 (0.95, 1.45)0.13
EtFOSAA1.17 (1.05, 1.31)1.18 (1.01, 1.39)1.14 (0.96, 1.36)0.62
MeFOSAA0.99 (0.86, 1.14)0.89 (0.74, 1.07)1.10 (0.89, 1.38)0.08
PFNA1.05 (0.91, 1.21)1.02 (0.83, 1.25)1.08 (0.86, 1.36)0.46
  • PFOS = n-PFOS + Sm-PFOS + Sm2-PFOS. PFOA = n-PFOA + Sb-PFOA. n-PFOA, linear PFOA; n-PFOS, linear PFOS; Sm-PFOS, perfluoromethylheptane sulfonic acids.

  • aAdjusted for participant sex, race/ethnicity, age, and baseline marital status, education, income, smoking history, BMI, maternal diabetes, paternal diabetes, baseline fasting glucose, baseline HbA1c levels, and treatment assignment if not stratified.

  • Statistically significant results appear in boldface type.